Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
Ann Neurol 50:121-127, McDonald,W.I.,et al, 2001
Practice Parameter: The Usefulness of Evoked Potentials in Identifying Clinically Silent Lesions in Patients With Suspected Multiple Sclerosis (an Evidence-Based Review)
Neurol 54:1720-1725, Gronseth,G.S.&Ashman,E.J., 2000
Visual Impairment in Children with Epilepsy Treated with Vigabatrin
Ann Neurol 48:60-64, Gross-Tsur,V. et al, 2000
Infantile Neuroaxonal Dystrophy,Clinical Spectrum and Diagnostic Criteria
Neurol 52:1472-1478, Nardocci,N.,et al, 1999
Intra-arterial Cisplatin-Associated Optic and Otic Toxicity
Arch Neurol 49:83-86, Maiese,K.,et al, 1992
Neurosarcoidosis:Signs, Course and Treatment in 35 Confirmed Cases
Medicine 69:261-276, Chapelon,C.,et al, 1990
Disturbance of Cerebral Function by Aluminium in Haemodialysis Patients without Overt Aluminium Toxicity
Lancet 2:7-12, Altmann,P.,et al, 1989
Cortical Blindness:Etiology, Diagnosis, & Prognosis
Ann Neurol 21:149-158, Aldrich,M.S.,et al, 1987
Visual & Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine Infusions
NEJM 314:869-873, Olivieri,N.F.,et al, 1986
New Diagnostic Criteria for Multiple Sclerosis:Guidelines for Research Protocols
Neurol 13:227-231, Poser,C.M.,et al, 1983
Carotid Occlusive Disease, Effect of Bright Light on Visual Evoked Response
Arch Neurol 39:687-689, Donnan,G.A.,et al, 1982
Central Achromatopsia:Behavioral, Anatomic, & Physiologic Aspects
Neurol 30:1064-1071, Damasio,A.,et al, 1980
Toluene Optic Neuropathy
Ann Neurol 4:390, Keane,J.R., 1978